Eli Lilly and Company $LLY Shares Acquired by New York State Teachers Retirement System

Key Points

• New York State Teachers Retirement System modestly increased its Eli Lilly stake in the first quarter, buying 1,088 more shares and bringing its holdings to 644,096 shares worth about $592.4 million.
• Eli Lilly reported strong first-quarter earnings, with EPS of $8.55 beating estimates and revenue of $19.8 billion topping forecasts; revenue rose 55.5% year over year.
• The company also announced a quarterly dividend of $1.73 per share, payable September 10, and analysts remain generally positive, with a consensus rating of Moderate Buy and an average price target of $1,235.07.

New York State Teachers Retirement System lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 644,096 shares of the company's stock after purchasing an additional 1,088 shares during the period. Eli Lilly and Company comprises about 1.2% of New York State Teachers Retirement System's investment portfolio, making the stock its 12th biggest holding. New York State Teachers Retirement System owned about 0.07% of Eli Lilly and Company worth $592,420,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after acquiring an additional 16 shares in the last quarter. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $30,000. Finally, Maseco LLP lifted its stake in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after purchasing an additional 28 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,208.37 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.14 trillion, a PE ratio of 42.93, a P/E/G ratio of 1.51 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,238.00. The business's fifty day moving average price is $1,065.45 and its two-hundred day moving average price is $1,028.14.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 earnings per share. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 35.74 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Coverage highlighted Eli Lilly as a leader in GLP-1 therapies with an expanding pipeline and diversified growth strategy, reinforcing the bull case despite the stock’s premium valuation. Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
• Positive Sentiment: Shares were lifted by optimism around GLP-1 Medicare inclusion and strong reported results, which investors view as supportive of continued demand and revenue growth. Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
• Positive Sentiment: Another bullish note argued that artificial intelligence could become a long-term growth tailwind for Eli Lilly by improving drug development and operational efficiency. AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
• Positive Sentiment: Repeated mentions in pharmaceutical and medical stock roundups suggest Lilly remains one of the sector’s preferred large-cap names for investors seeking growth exposure. Pharmaceutical Stocks To Follow Now - July 2nd
• Positive Sentiment: Additional commentary pointed to Lilly’s appeal to long-term, high-conviction investors, including billionaire hedge fund manager Cliff Asness, adding to the stock’s credibility as a favored healthcare holding. Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
• Neutral Sentiment: One item noted a leadership change at Lilly Korea, which appears operationally routine and unlikely to move the stock on its own. Eli Lilly Korea names Komasu Seiya new representative
• Neutral Sentiment: General industry pieces about pharmaceutical growth and the sector’s $2 trillion sales trajectory are supportive of sentiment, but they do not add a specific new catalyst for Lilly. Can pharma sustain its $2T trajectory?

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a "buy" rating in a report on Tuesday, May 26th. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday. Finally, Barclays raised their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,235.07.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.